On April 25, 2024, Regeneron Pharmaceuticals, Inc announced that it has received a shareholder proposal from John Chevedden, request that the Company board take each step necessary so that each voting requirement in the Company charter and bylaws (that is explicit or implicit due to default to state law) that calls for a greater than simple majority vote be replaced by a requirement for a majority of the votes cast for and against applicable proposals, or a simple majority in compliance with applicable laws. In addition, the Company urged the shareholders to vote against the shareholder proposal at its annual general meeting of shareholders scheduled to be held on June 14, 2024.